Core Viewpoint - Xinhua Medical's four-limb rehabilitation training device features a precise linkage structure, diverse training modes, and strong adaptability, providing high cost-performance due to large-scale production and nationwide after-sales service network with efficient response and full-cycle support [1] Group 1 - The four-limb rehabilitation training device utilizes a precise linkage structure [1] - The training modes are diverse and adaptable [1] - The pricing benefits from large-scale production, offering high cost-performance [1] Group 2 - The after-sales service covers a nationwide network [1] - The company ensures efficient response and full-cycle support for its products [1]

Core Viewpoint - The announcement highlights that Xinhua Medical's subsidiary has received a Class II medical device registration certificate for a new rehabilitation product, which is expected to enhance the company's competitive edge in the rehabilitation market [1][5]. Group 1: Medical Device Registration Details - The product is named "Four-Limb Linked Rehabilitation Training Device" and has been registered under the certificate number 陕械注准20262190001 [1][2]. - The registration was granted by the Shaanxi Provincial Drug Administration, with the approval date being January 23, 2026, and it is valid until January 22, 2031 [3]. - The device is designed to assist in improving limb strength and coordination, as well as enhancing joint mobility for patients with neurological or motor system injuries [2][4]. Group 2: Product Features and Applications - The device features a mechanical structure that allows for synchronized movement of limbs, aiding in rehabilitation for conditions such as hemiplegia and joint injuries [4]. - It is intended for use in stroke rehabilitation, improving blood circulation and metabolism in muscles, bones, and ligaments, while also enhancing strength, endurance, and balance [4]. Group 3: Impact on Company Performance - The approval of the Four-Limb Linked Rehabilitation Training Device is expected to meet the rehabilitation needs of patients with neurological or motor system injuries, thereby enriching Xinhua Medical's product line and enhancing its core competitiveness [5].

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

Core Viewpoint - Xinhua Medical (600587.SH) has received a medical device registration certificate for its product, the Limb Coordination Rehabilitation Training Device, from the Shaanxi Provincial Drug Administration [1] Group 1 - The product is developed by Xinhua Medical's wholly-owned subsidiary, Xinhua Medical Rehabilitation Industry (Xi'an) Co., Ltd [1] - The registration certificate signifies regulatory approval, which may enhance the company's market position in the rehabilitation equipment sector [1]